Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05154669 · ClinicalTrials.gov registry record · Phase 3

Integrating Financial Coaching and Smoking Cessation Coaching

A Phase 3 study of Smoking, sponsored by NYU Langone Health.

Recruiting
Registry status
Phase 3
Development phase
488
Enrollment target
1
Study location

NCT05154669 is a Phase 3 study of Smoking that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 488 participants, roughly in line with the 451-participant average among 123 other Smoking trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05154669, a Phase 3 study of Smoking, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
Phase 3
Development phase
488 participants
Enrollment target
1
Study location

Study Summary

This study conduct a two-arm, parallel-group randomized controlled trial. The study will recruit and randomize 900 smokers (n=450 per arm) to either: (1) Control: Standard Smoking Cessation Counseling or (2) Intervention: Integrated Financial-Smoking Cessation Counseling.

Conditions Studied

Interventions

  • OTHER Financial counseling
  • DRUG Nicotine Replacement Therapy Agent - Patches
  • DRUG Nicotine Replacement Therapy Agent - Lozenges
  • DRUG Nicotine Replacement Therapy Agent - Gum

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 488 participants
Start Date 2022-12-08
Est. Completion 2027-12-01
Phase Phase 3

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT05154669

The ClinicalTrials.gov registry entry for NCT05154669 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 451-participant average among 123 other Smoking trials with a reported enrollment target. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 4 interventions - of which Financial counseling is the first listed.

NCT05154669 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05154669 about?

NCT05154669 is a clinical study titled "Integrating Financial Coaching and Smoking Cessation Coaching". This study conduct a two-arm, parallel-group randomized controlled trial. The study will recruit and randomize 900 smokers (n=450 per arm) to either: (1) Control: Standard Smoking Cessation Counseling or (2) Intervention: Integrated Financial-Smoking Cessation Counseling.

What is the current status of trial NCT05154669?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 488 participants. The study started on 2022-12-08. Estimated completion is 2027-12-01.

What conditions does trial NCT05154669 study?

This clinical trial studies the following conditions: Smoking.

What interventions are being tested in trial NCT05154669?

The interventions under investigation include: Financial counseling (OTHER), Nicotine Replacement Therapy Agent - Patches (DRUG), Nicotine Replacement Therapy Agent - Lozenges (DRUG), Nicotine Replacement Therapy Agent - Gum (DRUG).

Who is sponsoring clinical trial NCT05154669?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05154669 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.